AQR Capital Management LLC reduced its position in DaVita Inc. (NYSE:DVA - Free Report) by 12.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,987 shares of the company's stock after selling 12,307 shares during the quarter. AQR Capital Management LLC owned approximately 0.11% of DaVita worth $13,009,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in DVA. Wellington Management Group LLP boosted its stake in shares of DaVita by 9.1% during the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock worth $405,000 after acquiring an additional 227 shares in the last quarter. Franklin Resources Inc. lifted its holdings in DaVita by 134.6% in the 3rd quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock worth $8,885,000 after purchasing an additional 31,502 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of DaVita by 201.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company's stock worth $11,159,000 after purchasing an additional 49,885 shares during the period. Hussman Strategic Advisors Inc. grew its holdings in shares of DaVita by 200.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock worth $3,769,000 after purchasing an additional 16,800 shares in the last quarter. Finally, Nordea Investment Management AB lifted its stake in DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock worth $39,712,000 after purchasing an additional 12,339 shares during the period. 90.12% of the stock is currently owned by institutional investors.
DaVita Stock Down 0.0 %
Shares of DVA stock traded down $0.01 during midday trading on Friday, reaching $143.62. 664,520 shares of the stock were exchanged, compared to its average volume of 817,774. The firm has a market cap of $11.04 billion, a PE ratio of 13.37, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The company's 50 day moving average is $145.81 and its two-hundred day moving average is $154.08. DaVita Inc. has a 1 year low of $131.44 and a 1 year high of $179.60. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.
DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on DVA shares. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Cowen reaffirmed a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays increased their price target on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $166.33.
Get Our Latest Research Report on DVA
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
